Clinical | All Blog Posts | PerkinElmer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the AlphaLISA human PD-L1 assay.

New Earlier Screen For Pregnant Women

North York General Hospital researchers have developed an Enhanced First Trimester Screen that is faster, less costly, but just as accurate as the standard Integrated Prenatal Screening protocol in detecting the risk for Down syndrome and Trisomy 18. The new test was developed with the help of PerkinElmer and is now in use in Ontario, Canada.

Innovators in Cancer Immunology: Squamous Cell Carcinoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a squamous cell carcinoma cancer case study, Dr. Fox uses the instrumentation to help develop predictive biomarkers.

Battling Sickle Cell Disease At Its Source

Sub-Saharan Africa has the highest percentage of births with sickle cell disease. Dr. Russell E. Ware and PerkinElmer are collaborating to train African medical technicians to conduct SCD screening on their own.